摘要
目的探讨乳岩汤联合新辅助化疗对三阴性乳腺癌(TNBC)患者近期疗效、免疫功能及生存预后的影响。方法选取2020年5月至2023年5月于河北一洲肿瘤医院接受治疗的TNBC患者88例,按照随机数字表法分为对照组与乳岩汤组,各44例。对照组患者接受AC-T序贯化疗方案治疗,乳岩汤组患者在对照组基础上采用乳岩汤进行联合治疗,持续4个疗程。比较两组患者近期疗效、免疫功能指标水平、治疗期间不良反应发生情况、生存预后。结果乳岩汤组疗效分级、总缓解率优于对照组(P<0.05);治疗4个疗程后,两组NK细胞、总T细胞、Th细胞计数百分率降低(P<0.05),且乳岩汤组NK细胞、总T细胞、Th细胞计数百分率低于对照组(P<0.05)。两组治疗期间不良反应发生情况差异无统计学意义(P>0.05)。随访1年期间,乳岩汤组复发转移率较对照组低(P<0.05),无病生存时间较对照组长(P<0.05)。结论乳岩汤联合新辅助化疗治疗TNBC,相较于单纯新辅助化疗,近期及远期疗效更为确切,这与其调节患者免疫功能的作用机制密切相关。
Objective To explore the effects of Ruyan Decoction combined with neoadjuvant chemotherapy on short-term efficacy,immune function and survival prognosis of patients with triple-negative breast cancer.Methods A total of 88 TNBC patients who were treated at Hebei Yizhou Cancer Hospital from May 2020 to May 2023 were selected and divided into the control group and the Ruyan Decoction group according to the random number table method,with 44 cases in each group.Patients in the control group received sequential chemotherapy regimens of AC-T,while patients in the Ruyan Decoction group were treated with combined treatment with Ruyan Decoction on the basis of the control group for 4 courses.Short-term efficacy,immune function index levels,occurrence of adverse reactions during treatment,survival prognosis of the two groups of patients were compared.Results The therapeutic effect classification and total remission rate of the Ruyan Decoction group were better than those of the control group(P<0.05).After 4 courses of treatment,the percentages of NK cell,total T cell and Th cell counts in both groups decreased(P<0.05),percentages of NK cell,total T cell and Th cell counts in the Ruyan Decoction group were lower than those in the control group(P<0.05).There was no statistically significant difference in occurrence of adverse reactions during treatment between two groups of patients(P>0.05).During 1-year follow-up period,the recurrence and metastasis rate in the Ruyan Decoction group was lower than that in the control group(P<0.05),and the disease-free survival time was longer than that in the control group(P<0.05).Conclusion The combination of Ruyan Decoction and neoadjuvant chemotherapy in the treatment of TNBC has more definite short-term and long-term efficacy compared with neoadjuvant chemotherapy alone,which is closely related to its mechanism of regulating the immune function of patients.
作者
袁英侠
聂玉倩
穆怀伟
YUAN Ying-Xia;NIE Yu-Qian;MU Huai-Wei(Department of Oncology,Hebei Yizhou Cancer Hospital,Baoding 072750,China;Department of Radiotherapy VI,Hebei Yizhou Cancer Hospital,Baoding 072750,China;Department of Integrated Traditional Chinese and Western Medicine Oncology,Jinshazhou Hospital,Guangzhou University of Chinese Medicine,Guangzhou 510168,China)
出处
《中国药物经济学》
2025年第7期50-53,共4页
China Journal of Pharmaceutical Economics
关键词
三阴性乳腺癌
乳岩汤
新辅助化疗
免疫功能
生存预后
Triple-negative breast cancer
Ruyan Decoction
Neoadjuvant chemotherapy
Immune function
Survival prognosis
